Clinical Trial Results:
A Randomized, Open-label Eculizumab and Ravulizumab Controlled, Non-Inferiority Study to Evaluate the Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients with Paroxysmal Nocturnal Hemoglobinuria who are Currently Treated with Eculizumab or Ravulizumab
Summary
|
|
EudraCT number |
2020-002761-33 |
Trial protocol |
IT DE ES FR PL GR |
Global end of trial date |
12 Jul 2023
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
25 Jul 2024
|
First version publication date |
25 Jul 2024
|
Other versions |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
R3918-PNH-2022
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT05131204 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Regeneron Pharmaceuticals, Inc.
|
||
Sponsor organisation address |
777 Old Saw Mill River Road, Tarrytown, NY, United States, 10591
|
||
Public contact |
Clinical Trials Administrator, Regeneron Pharmaceuticals, Inc., 001 844-734-6643, clinicaltrials@regeneron.com
|
||
Scientific contact |
Clinical Trials Administrator, Regeneron Pharmaceuticals, Inc., 001 844-734-6643, clinicaltrials@regeneron.com
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
|||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
12 Jul 2023
|
||
Is this the analysis of the primary completion data? |
No
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
12 Jul 2023
|
||
Was the trial ended prematurely? |
Yes
|
||
General information about the trial
|
|||
Main objective of the trial |
The primary objective of the study was:
To evaluate the effect of pozelimab and cemdisiran combination therapy on hemolysis, as assessed by lactate dehydrogenase (LDH), after 36 weeks of treatment, in participants with PNH who switch from eculizumab or ravulizumab therapy versus participants who continue their eculizumab or ravulizumab therapy.
|
||
Protection of trial subjects |
It is the responsibility of both the sponsor and the investigator(s) to ensure that this clinical study will be conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki, and that are consistent with the ICH guidelines for GCP and applicable regulatory requirements.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
06 Oct 2022
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
Yes
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Greece: 1
|
||
Country: Number of subjects enrolled |
Korea, Republic of: 1
|
||
Country: Number of subjects enrolled |
Philippines: 1
|
||
Worldwide total number of subjects |
3
|
||
EEA total number of subjects |
1
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
3
|
||
From 65 to 84 years |
0
|
||
85 years and over |
0
|
|
||||||||||||||||
Recruitment
|
||||||||||||||||
Recruitment details |
- | |||||||||||||||
Pre-assignment
|
||||||||||||||||
Screening details |
A total of 140 participants were expected to be enrolled, however, due to feasibility: five participants were screened and 3 were randomized and treated. There were 2 screen failures. | |||||||||||||||
Period 1
|
||||||||||||||||
Period 1 title |
Overall study (overall period)
|
|||||||||||||||
Is this the baseline period? |
Yes | |||||||||||||||
Allocation method |
Randomised - controlled
|
|||||||||||||||
Blinding used |
Not blinded | |||||||||||||||
Arms
|
||||||||||||||||
Are arms mutually exclusive |
Yes
|
|||||||||||||||
Arm title
|
Pozelimab and Cemdisiran | |||||||||||||||
Arm description |
Randomized 1:1 | |||||||||||||||
Arm type |
Experimental | |||||||||||||||
Investigational medicinal product name |
Pozelimab
|
|||||||||||||||
Investigational medicinal product code |
R3918
|
|||||||||||||||
Other name |
||||||||||||||||
Pharmaceutical forms |
Cutaneous liquid
|
|||||||||||||||
Routes of administration |
Intravenous use
|
|||||||||||||||
Dosage and administration details |
Administered per protocol
|
|||||||||||||||
Investigational medicinal product name |
Ravulizumab
|
|||||||||||||||
Investigational medicinal product code |
ALXN1210
|
|||||||||||||||
Other name |
Ultomiris
|
|||||||||||||||
Pharmaceutical forms |
Cutaneous liquid
|
|||||||||||||||
Routes of administration |
Intravenous use
|
|||||||||||||||
Dosage and administration details |
Administered per protocol
|
|||||||||||||||
Investigational medicinal product name |
Eculizumab
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
Soliris
|
|||||||||||||||
Pharmaceutical forms |
Cutaneous liquid
|
|||||||||||||||
Routes of administration |
Intravenous use
|
|||||||||||||||
Dosage and administration details |
Administered per protocol
|
|||||||||||||||
Investigational medicinal product name |
Cemdisiran
|
|||||||||||||||
Investigational medicinal product code |
ALN-CC5
|
|||||||||||||||
Other name |
||||||||||||||||
Pharmaceutical forms |
Cutaneous liquid
|
|||||||||||||||
Routes of administration |
Subcutaneous use
|
|||||||||||||||
Dosage and administration details |
Administered per protocol
|
|||||||||||||||
Arm title
|
Anti-C5 standard-of-care | |||||||||||||||
Arm description |
Randomized 1:1 | |||||||||||||||
Arm type |
Experimental | |||||||||||||||
Investigational medicinal product name |
Ravulizumab
|
|||||||||||||||
Investigational medicinal product code |
ALXN1210
|
|||||||||||||||
Other name |
Ultomiris
|
|||||||||||||||
Pharmaceutical forms |
Cutaneous liquid
|
|||||||||||||||
Routes of administration |
Intravenous use
|
|||||||||||||||
Dosage and administration details |
Administered per protocol
|
|||||||||||||||
Investigational medicinal product name |
Eculizumab
|
|||||||||||||||
Investigational medicinal product code |
||||||||||||||||
Other name |
Soliris
|
|||||||||||||||
Pharmaceutical forms |
Cutaneous liquid
|
|||||||||||||||
Routes of administration |
Intravenous use
|
|||||||||||||||
Dosage and administration details |
Administered per protocol
|
|||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Pozelimab and Cemdisiran
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Randomized 1:1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Anti-C5 standard-of-care
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Randomized 1:1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Pozelimab and Cemdisiran
|
||
Reporting group description |
Randomized 1:1 | ||
Reporting group title |
Anti-C5 standard-of-care
|
||
Reporting group description |
Randomized 1:1 |
|
|||||||||||||
End point title |
Percent change in lactate dehydrogenase (LDH) from baseline to week 36 [1] | ||||||||||||
End point description |
|||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
Baseline to week 36
|
||||||||||||
Notes [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: No data was collected so no statistical analysis was completed. |
|||||||||||||
|
|||||||||||||
Notes [2] - Due to Early Termination, endpoint removed from Statistical Analysis Plan. Data not collected. [3] - Due to Early Termination, endpoint removed from Statistical Analysis Plan. Data not collected. |
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Percentage of participants with transfusion avoidance after day 1 through week 36 | ||||||||||||
End point description |
|||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Day 1 through week 36
|
||||||||||||
|
|||||||||||||
Notes [4] - Due to Early Termination, endpoint removed from Statistical Analysis Plan. Data not collected. [5] - Due to Early Termination, endpoint removed from Statistical Analysis Plan. Data not collected. |
|||||||||||||
No statistical analyses for this end point |
|
|||||||||||||
End point title |
Percentage of participants with transfusion avoidance from week 4 through week 36 | ||||||||||||
End point description |
|||||||||||||
End point type |
Secondary
|
||||||||||||
End point timeframe |
Week 4 through week 36
|
||||||||||||
|
|||||||||||||
Notes [6] - Due to Early Termination, endpoint removed from Statistical Analysis Plan. Data not collected. [7] - Due to Early Termination, endpoint removed from Statistical Analysis Plan. Data not collected. |
|||||||||||||
No statistical analyses for this end point |
|
||||||||||
End point title |
Percentage of participants with breakthrough hemolysis after day 1 through week 36 | |||||||||
End point description |
||||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
Day 1 through week 36
|
|||||||||
|
||||||||||
Notes [8] - Due to Early Termination, endpoint removed from Statistical Analysis Plan. Data not collected. [9] - Due to Early Termination, endpoint removed from Statistical Analysis Plan. Data not collected. |
||||||||||
No statistical analyses for this end point |
|
||||||||||
End point title |
Percentage of participants with hemoglobin stabilization after day 1 through week 36 | |||||||||
End point description |
||||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
Day 1 through week 36
|
|||||||||
|
||||||||||
Notes [10] - Due to Early Termination, endpoint removed from Statistical Analysis Plan. Data not collected. [11] - Due to Early Termination, endpoint removed from Statistical Analysis Plan. Data not collected. |
||||||||||
No statistical analyses for this end point |
|
||||||||||
End point title |
Percentage of participants with breakthrough hemolysis from week 4 through week 36 | |||||||||
End point description |
||||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
Week 4 through week 36
|
|||||||||
|
||||||||||
Notes [12] - Due to Early Termination, endpoint removed from Statistical Analysis Plan. Data not collected. [13] - Due to Early Termination, endpoint removed from Statistical Analysis Plan. Data not collected. |
||||||||||
No statistical analyses for this end point |
|
||||||||||
End point title |
Percentage of participants with hemoglobin stabilization from week 4 through week 36 | |||||||||
End point description |
||||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
Week 4 through week 36
|
|||||||||
|
||||||||||
Notes [14] - Due to Early Termination, endpoint removed from Statistical Analysis Plan. Data not collected. [15] - Due to Early Termination, endpoint removed from Statistical Analysis Plan. Data not collected. |
||||||||||
No statistical analyses for this end point |
|
||||||||||
End point title |
Percentage of participants who maintained adequate control of hemolysis from week 8 through week 36 | |||||||||
End point description |
||||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
Week 8 through week 36
|
|||||||||
|
||||||||||
Notes [16] - Due to Early Termination, endpoint removed from Statistical Analysis Plan. Data not collected. [17] - Due to Early Termination, endpoint removed from Statistical Analysis Plan. Data not collected. |
||||||||||
No statistical analyses for this end point |
|
||||||||||
End point title |
Percentage of participants with adequate control of LDH after day 1 though week 36 | |||||||||
End point description |
||||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
Day 1 through week 36
|
|||||||||
|
||||||||||
Notes [18] - Due to Early Termination, endpoint removed from Statistical Analysis Plan. Data not collected. [19] - Due to Early Termination, endpoint removed from Statistical Analysis Plan. Data not collected. |
||||||||||
No statistical analyses for this end point |
|
||||||||||
End point title |
Percentage of participants with adequate control of LDH from week 8 through week 36 | |||||||||
End point description |
||||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
Week 8 through week 36
|
|||||||||
|
||||||||||
Notes [20] - Due to Early Termination, endpoint removed from Statistical Analysis Plan. Data not collected. [21] - Due to Early Termination, endpoint removed from Statistical Analysis Plan. Data not collected. |
||||||||||
No statistical analyses for this end point |
|
||||||||||
End point title |
Percentage of participants with normalization of LDH after day 1 through week 36 | |||||||||
End point description |
||||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
Day 1 through week 36
|
|||||||||
|
||||||||||
Notes [22] - Due to Early Termination, endpoint removed from Statistical Analysis Plan. Data not collected. [23] - Due to Early Termination, endpoint removed from Statistical Analysis Plan. Data not collected. |
||||||||||
No statistical analyses for this end point |
|
||||||||||
End point title |
Percentage of participants with normalization of LDH from week 8 through week 36 | |||||||||
End point description |
||||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
Week 8 through week 36
|
|||||||||
|
||||||||||
Notes [24] - Due to Early Termination, endpoint removed from Statistical Analysis Plan. Data not collected. [25] - Due to Early Termination, endpoint removed from Statistical Analysis Plan. Data not collected. |
||||||||||
No statistical analyses for this end point |
|
||||||||||
End point title |
Percentage of participants who maintained adequate control of hemolysis after day 1 through week 36 | |||||||||
End point description |
||||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
After day 1 through week 36
|
|||||||||
|
||||||||||
Notes [26] - Due to Early Termination, endpoint removed from Statistical Analysis Plan. Data not collected. [27] - Due to Early Termination, endpoint removed from Statistical Analysis Plan. Data not collected. |
||||||||||
No statistical analyses for this end point |
|
||||||||||
End point title |
Change in fatigue as measured by the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) Scale from Baseline to Week 36 | |||||||||
End point description |
||||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
Baseline to week 36
|
|||||||||
|
||||||||||
Notes [28] - Due to Early Termination, endpoint removed from Statistical Analysis Plan. Data not collected. [29] - Due to Early Termination, endpoint removed from Statistical Analysis Plan. Data not collected. |
||||||||||
No statistical analyses for this end point |
|
||||||||||
End point title |
Change in global health status (GHS)/QoL scale score on the EORTC-QLQ-C30 from baseline to week 36 | |||||||||
End point description |
||||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
Baseline to week 36
|
|||||||||
|
||||||||||
Notes [30] - Due to Early Termination, endpoint removed from Statistical Analysis Plan. Data not collected. [31] - Due to Early Termination, endpoint removed from Statistical Analysis Plan. Data not collected. |
||||||||||
No statistical analyses for this end point |
|
||||||||||
End point title |
Change in Physical Function (PF) score on the European organization for research and treatment of cancer quality-of-Life questionnaire Core 30 Items (EORTC-QLQ-C30) from baseline to week 36 | |||||||||
End point description |
||||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
Baseline to week 36
|
|||||||||
|
||||||||||
Notes [32] - Due to Early Termination, endpoint removed from Statistical Analysis Plan. Data not collected. [33] - Due to Early Termination, endpoint removed from Statistical Analysis Plan. Data not collected. |
||||||||||
No statistical analyses for this end point |
|
||||||||||
End point title |
Rate of RBCs transfused per protocol algorithm after day 1 through week 36 | |||||||||
End point description |
||||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
After day 1 through week 36
|
|||||||||
|
||||||||||
Notes [34] - Due to Early Termination, endpoint removed from Statistical Analysis Plan. Data not collected. [35] - Due to Early Termination, endpoint removed from Statistical Analysis Plan. Data not collected. |
||||||||||
No statistical analyses for this end point |
|
||||||||||
End point title |
Rate of RBCs transfused per protocol algorithm from week 4 through week 36 | |||||||||
End point description |
||||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
Week 4 through week 36
|
|||||||||
|
||||||||||
Notes [36] - Due to Early Termination, endpoint removed from Statistical Analysis Plan. Data not collected. [37] - Due to Early Termination, endpoint removed from Statistical Analysis Plan. Data not collected. |
||||||||||
No statistical analyses for this end point |
|
||||||||||
End point title |
Number of units of RBCs transfused per protocol algorithm after day 1 through week 36 | |||||||||
End point description |
||||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
After day 1 through week 36
|
|||||||||
|
||||||||||
Notes [38] - Due to Early Termination, endpoint removed from Statistical Analysis Plan. Data not collected. [39] - Due to Early Termination, endpoint removed from Statistical Analysis Plan. Data not collected. |
||||||||||
No statistical analyses for this end point |
|
||||||||||
End point title |
Number of units of RBCs transfused per protocol algorithm from week 4 through week 36 | |||||||||
End point description |
||||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
Week 4 through week 36
|
|||||||||
|
||||||||||
Notes [40] - Due to Early Termination, endpoint removed from Statistical Analysis Plan. Data not collected. [41] - Due to Early Termination, endpoint removed from Statistical Analysis Plan. Data not collected. |
||||||||||
No statistical analyses for this end point |
|
||||||||||
End point title |
Change in hemoglobin levels from baseline to week 36 | |||||||||
End point description |
||||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
Baseline to week 36
|
|||||||||
|
||||||||||
Notes [42] - Due to Early Termination, endpoint removed from Statistical Analysis Plan. Data not collected. [43] - Due to Early Termination, endpoint removed from Statistical Analysis Plan. Data not collected. |
||||||||||
No statistical analyses for this end point |
|
||||||||||
End point title |
Incidence and severity of treatment emergent serious adverse events (SAEs) over 36 weeks | |||||||||
End point description |
||||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
Over 36 weeks
|
|||||||||
|
||||||||||
Notes [44] - Due to Early Termination, endpoint removed from Statistical Analysis Plan. Data not collected. [45] - Due to Early Termination, endpoint removed from Statistical Analysis Plan. Data not collected. |
||||||||||
No statistical analyses for this end point |
|
||||||||||
End point title |
Incidence and severity of treatment-emergent adverse events (TEAEs) of special interest over 36 weeks | |||||||||
End point description |
||||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
Over week 36
|
|||||||||
|
||||||||||
Notes [46] - Due to Early Termination, endpoint removed from Statistical Analysis Plan. Data not collected. [47] - Due to Early Termination, endpoint removed from Statistical Analysis Plan. Data not collected. |
||||||||||
No statistical analyses for this end point |
|
||||||||||
End point title |
Incidence and severity TEAEs leading to treatment discontinuation over 36 weeks | |||||||||
End point description |
||||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
Over week 36
|
|||||||||
|
||||||||||
Notes [48] - Due to Early Termination, endpoint removed from Statistical Analysis Plan. Data not collected. [49] - Due to Early Termination, endpoint removed from Statistical Analysis Plan. Data not collected. |
||||||||||
No statistical analyses for this end point |
|
||||||||||
End point title |
Change in total CH50 from baseline to week 36 | |||||||||
End point description |
||||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
Baseline to week 36
|
|||||||||
|
||||||||||
Notes [50] - Due to Early Termination, endpoint removed from Statistical Analysis Plan. Data not collected. [51] - Due to Early Termination, endpoint removed from Statistical Analysis Plan. Data not collected. |
||||||||||
No statistical analyses for this end point |
|
||||||||||
End point title |
Concentrations of total cemdisiran in plasma through week 32 | |||||||||
End point description |
||||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
Baseline through week 32
|
|||||||||
|
||||||||||
Notes [52] - Due to Early Termination, endpoint removed from Statistical Analysis Plan. Data not collected. [53] - Due to Early Termination, endpoint removed from Statistical Analysis Plan. Data not collected. |
||||||||||
No statistical analyses for this end point |
|
||||||||||
End point title |
Concentrations of total pozelimab in serum through week 62 | |||||||||
End point description |
||||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
Baseline through week 62
|
|||||||||
|
||||||||||
Notes [54] - Due to Early Termination, endpoint removed from Statistical Analysis Plan. Data not collected. [55] - Due to Early Termination, endpoint removed from Statistical Analysis Plan. Data not collected. |
||||||||||
No statistical analyses for this end point |
|
||||||||||
End point title |
Concentration of total C5 in plasma through week 62 | |||||||||
End point description |
||||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
Baseline to week 62
|
|||||||||
|
||||||||||
Notes [56] - Due to Early Termination, endpoint removed from Statistical Analysis Plan. Data not collected. [57] - Due to Early Termination, endpoint removed from Statistical Analysis Plan. Data not collected. |
||||||||||
No statistical analyses for this end point |
|
||||||||||
End point title |
Percent change in total CH50 from baseline to week 36 | |||||||||
End point description |
||||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
Baseline to week 36
|
|||||||||
|
||||||||||
Notes [58] - Due to Early Termination, endpoint removed from Statistical Analysis Plan. Data not collected. [59] - Due to Early Termination, endpoint removed from Statistical Analysis Plan. Data not collected. |
||||||||||
No statistical analyses for this end point |
|
||||||||||
End point title |
Concentrations of total ravulizumab in plasma through week 44 | |||||||||
End point description |
||||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
Baseline through week 44
|
|||||||||
|
||||||||||
Notes [60] - Due to Early Termination, endpoint removed from Statistical Analysis Plan. Data not collected. [61] - Due to Early Termination, endpoint removed from Statistical Analysis Plan. Data not collected. |
||||||||||
No statistical analyses for this end point |
|
||||||||||
End point title |
Concentrations of total eculizumab in serum through week 40 | |||||||||
End point description |
||||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
Baseline through week 40
|
|||||||||
|
||||||||||
Notes [62] - Due to Early Termination, endpoint removed from Statistical Analysis Plan. Data not collected. [63] - Due to Early Termination, endpoint removed from Statistical Analysis Plan. Data not collected. |
||||||||||
No statistical analyses for this end point |
|
||||||||||
End point title |
Incidence of treatment emergent anti-drug antibodies (ADAs) to pozelimab through week 62 | |||||||||
End point description |
||||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
Baseline through week 62
|
|||||||||
|
||||||||||
Notes [64] - Due to Early Termination, endpoint removed from Statistical Analysis Plan. Data not collected. [65] - Due to Early Termination, endpoint removed from Statistical Analysis Plan. Data not collected. |
||||||||||
No statistical analyses for this end point |
|
||||||||||
End point title |
Incidence of treatment emergent ADAs to cemdisiran through week 62 | |||||||||
End point description |
||||||||||
End point type |
Secondary
|
|||||||||
End point timeframe |
Baseline through week 62
|
|||||||||
|
||||||||||
Notes [66] - Due to Early Termination, endpoint removed from Statistical Analysis Plan. Data not collected. [67] - Due to Early Termination, endpoint removed from Statistical Analysis Plan. Data not collected. |
||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
From first dose to week 29
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
26.0
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Pozelimab Q4W and Cemdisiran
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Randomized 1:1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Anti-C5 standard-of-care
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Randomized 1:1 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
21 Jun 2022 |
Main purpose for this amendment was to include new secondary endpoints and provide details on the planned analyses. |
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
20Dec2022 - sponsor decided to terminate study due to feasability challenges related to enrollment. There were no safety or efficacy concerns. |